Uniqure NVNASDAQ:QURE
- LAST PRICE3.9537
- TODAY'S CHANGE (%)-0.0563 (-1.4040%)
- Bid / Lots3.9500/ 5
- Ask / Lots3.9600/ 7
- Open / Previous Close4.0100 / 4.0100
- Day Range
- 52 Week Range
- Volume408,116
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QURE |
|---|---|---|
| 09:32 ET | 8931 | 3.99 |
| 09:34 ET | 5557 | 4 |
| 09:36 ET | 8240 | 3.98 |
| 09:38 ET | 1961 | 3.98 |
| 09:39 ET | 1296 | 3.97 |
| 09:41 ET | 29359 | 3.94 |
| 09:43 ET | 8405 | 3.97 |
| 09:45 ET | 2100 | 3.95 |
| 09:48 ET | 4100 | 3.95 |
| 09:50 ET | 1347 | 3.9826 |
| 09:52 ET | 4791 | 3.97 |
| 09:54 ET | 1673 | 3.94 |
| 09:56 ET | 8654 | 3.925 |
| 09:57 ET | 15588 | 3.94 |
| 09:59 ET | 7416 | 3.945 |
| 10:01 ET | 6778 | 3.935 |
| 10:03 ET | 3842 | 3.93 |
| 10:06 ET | 3055 | 3.93 |
| 10:08 ET | 1713 | 3.9499 |
| 10:10 ET | 2400 | 3.955 |
| 10:12 ET | 13893 | 3.965 |
| 10:14 ET | 184 | 3.9634 |
| 10:15 ET | 6659 | 4.015 |
| 10:17 ET | 3505 | 4.03 |
| 10:19 ET | 13492 | 4.015 |
| 10:21 ET | 1100 | 4.03 |
| 10:24 ET | 1100 | 4.02 |
| 10:26 ET | 4424 | 4.04 |
| 10:28 ET | 706 | 4.03 |
| 10:32 ET | 865 | 4.01 |
| 10:33 ET | 2523 | 4 |
| 10:35 ET | 100 | 3.99 |
| 10:37 ET | 643 | 3.97 |
| 10:39 ET | 200 | 3.965 |
| 10:42 ET | 1011 | 3.955 |
| 10:44 ET | 1424 | 3.945 |
| 10:46 ET | 420 | 3.9491 |
| 10:48 ET | 14115 | 3.945 |
| 10:50 ET | 20742 | 3.94 |
| 10:51 ET | 700 | 3.945 |
| 10:53 ET | 1142 | 3.9125 |
| 10:55 ET | 1300 | 3.9099 |
| 10:57 ET | 958 | 3.9001 |
| 11:00 ET | 14145 | 3.91 |
| 11:02 ET | 2491 | 3.93 |
| 11:04 ET | 200 | 3.94 |
| 11:06 ET | 28835 | 3.95 |
| 11:08 ET | 18813 | 3.9401 |
| 11:09 ET | 500 | 3.925 |
| 11:11 ET | 2900 | 3.93 |
| 11:13 ET | 2700 | 3.92 |
| 11:15 ET | 11156 | 3.9325 |
| 11:18 ET | 4929 | 3.945 |
| 11:20 ET | 13983 | 3.955 |
| 11:22 ET | 1746 | 3.96 |
| 11:26 ET | 2728 | 3.955 |
| 11:27 ET | 3200 | 3.955 |
| 11:29 ET | 1143 | 3.96 |
| 11:31 ET | 1500 | 3.96 |
| 11:33 ET | 798 | 3.945 |
| 11:36 ET | 2326 | 3.96 |
| 11:42 ET | 200 | 3.965 |
| 11:44 ET | 1093 | 3.95 |
| 11:45 ET | 1812 | 3.955 |
| 11:47 ET | 200 | 3.955 |
| 11:49 ET | 534 | 3.95 |
| 11:51 ET | 1405 | 3.945 |
| 11:54 ET | 1400 | 3.95 |
| 11:56 ET | 1100 | 3.94 |
| 12:00 ET | 1708 | 3.945 |
| 12:02 ET | 1400 | 3.945 |
| 12:03 ET | 300 | 3.945 |
| 12:05 ET | 700 | 3.955 |
| 12:07 ET | 100 | 3.95 |
| 12:09 ET | 1800 | 3.9553 |
| 12:12 ET | 7303 | 3.96 |
| 12:14 ET | 200 | 3.959 |
| 12:16 ET | 300 | 3.9599 |
| 12:18 ET | 3658 | 3.95 |
| 12:20 ET | 1058 | 3.9537 |
Jul 1, 2024
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen, from 7:05AM ET on Monday Jul 01, 2024 by Dow Jones
7:05AM ET on Monday Jul 01, 2024 by Dow JonesGenezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA, from 7:05AM ET on Monday Jul 01, 2024 by Dow Jones
7:05AM ET on Monday Jul 01, 2024 by Dow JonesuniQure Announces Sale of Commercial Manufacturing Facility to Genezen, from 7:05AM ET on Monday Jul 01, 2024 by Dow Jones
7:05AM ET on Monday Jul 01, 2024 by Dow JonesPress Release: uniQure Announces Sale of Commercial Manufacturing Facility to Genezen, from 7:05AM ET on Monday Jul 01, 2024 by Dow Jones
7:05AM ET on Monday Jul 01, 2024 by Dow Jones*DJ Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE, from 7:05AM ET on Monday Jul 01, 2024 by Dow Jones
7:05AM ET on Monday Jul 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Uniqure NV | 194.7M | -0.6x | --- |
Lineage Cell Therapeutics Inc | 176.0M | -6.8x | --- |
Fennec Pharmaceuticals Inc | 164.8M | 164.1x | --- |
Mediwound Ltd | 144.5M | -10.6x | --- |
MeiraGTx Holdings PLC | 253.4M | -3.1x | --- |
TriSalus Life Sciences Inc | 137.4M | -2.6x | --- |
Company Information
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact Information
- Headquarters
- Paasheuvelweg 25aAMSTERDAM, Netherlands 1105 BP
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Meek
- Chief Executive Officer, Executive Director
- Matthew Kapusta
- Chief Financial Officer
- Christian Klemt
- Chief Operations Officer
- Pierre Caloz
- Chief Business and Scientific Officer
- Richard Porter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $194.7M |
|---|---|
Revenue (TTM) | $19.0M |
Shares Outstanding | 48.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-6.20 |
Book Value | $4.34 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 10.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,383.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
